Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Perils and Problems in Bispecific T-Cell Engager Antibodies
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsA...
Source: Current Drug Safety - February 29, 2024 Category: Drugs & Pharmacology Authors: Bisht Khushboo Joshi Rajat Kumar Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study
CONCLUSION: The findings show a high trend of inappropriate PPI prescriptions. Hence, educational programs are recommended to encourage healthcare professionals to stick to the approved guidelines when prescribing PPIs.PMID:38347790 | DOI:10.2174/0115748863284762240129092556 (Source: Current Drug Safety)
Source: Current Drug Safety - February 13, 2024 Category: Drugs & Pharmacology Authors: Abdulhamid Althagafi Nesren Magbool Hatoon Altayib Tala Bukhari Nawal Melibari Foud Bahamdain Khalid Eljaaly Source Type: research
